Total Funding
1
2
Total FundingSeries B raised
Growth Score
-4 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
388861
Synchroneuron is a biopharmaceutical company developing therapies for tardive dyskinesia and other related movement disorders.
William D Kerns: Co-founder & CEO- Barry S. Fogel: Founder & CSOPast Role: PointRight, Executive Vice President and Founder
About the Company
Synchroneuron is a biopharmaceutical company developing therapies for tardive dyskinesia and other related movement disorders. Its lead candidate SNC-102, a sustained-release formulation of acamprosate calcium is being evaluated in phase 2 trials for tardive dyskinesia (TD) and Tourette syndrome (TS) and in phase 1 trials for combat-related
posttraumatic stress disorder (cPTSD).
Women Founded
